The market has been down on Cyclacel Pharmaceuticals Inc (CYCC) stock recently. CYCC gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.
Cyclacel Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on CYCC!
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With CYCC Stock Today?
Cyclacel Pharmaceuticals Inc (CYCC) stock is trading at $2.01 as of 10:12 AM on Wednesday, Mar 27, an increase of $0.06, or 3.08% from the previous closing price of $1.95. The stock has traded between $1.98 and $2.09 so far today. Volume today is less active than usual. So far 2,285 shares have traded compared to average volume of 39,104 shares.
To screen for more stocks like Cyclacel Pharmaceuticals Inc click here.
More About Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.
Click Here to get the full Stock Report for Cyclacel Pharmaceuticals Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
